India Pharma Monitor

Pharmaceutical Industry in India

Market and Sector Headlines

Indian Market Growth

India’s pharmaceutical market is valued at USD 60.32 billion in 2026, growing at CAGR of 5.74% to reach USD 79.74 billion by 2031, according to Bain & Co projections expecting growth to USD 120-130 billion by 2030.

FY26 Growth Projection

Indian pharmaceutical sector is projected to post 7-9% revenue growth in FY26, with domestic market expanding 8-10% driven by sales force expansion, wider rural reach, and new product launches, while European revenues forecast to grow 10-12% following 18.9% jump last year.

Global Market Position

India ranks 3rd globally in pharmaceutical production by volume and 14th by value, producing 60,000+ generic drugs across 60 therapeutic categories, supplying 500+ APIs, and contributing 50% to global generic drug exports, earning it the title “Pharmacy of the World”.

US Market Challenges

US market remains challenging for Indian pharma with revenue growth expected to moderate to 3-5% in FY26 amid pricing pressures and continued USFDA regulatory scrutiny including warning letters, import alerts, and launch delays, though pharmaceuticals currently exempt from 50% US tariff on Indian imports.

International Market Size

The global pharmaceutical market is projected to reach USD 11 trillion by 2030, with CRDMO industry expected to double to Rs. 1,21,282 crore (USD 14 billion) by 2028, reinforcing India’s role in global supply chains and manufacturing excellence.

Government Policy Support

India announced Rs. 60,000 crore (USD 7 billion) API-push on December 5, 2025 to boost domestic pharmaceutical manufacturing and cut import dependence, with PLI scheme of Rs. 15,000 crore (USD 2.04 billion) for 2020-21 to 2028-29, and 16,912 Jan Aushadhi Kendras operational offering 2,110 medicines.

R&D Investment Trends

Indian pharmaceutical companies are increasing R&D investments to 6-7% of revenues, focusing on complex molecules and specialty products to sustain growth and mitigate external risks, with 87% lower R&D costs in India than developed countries and 30-35% lower manufacturing costs than US and Europe.

The Market and Sector Headlines section monitors pharma and stock across India's pharmaceutical sector. Significant developments around biotech continue to draw attention from regulators, investors, and industry professionals, reflecting the dynamic pace of change in this space.

Recent coverage has drawn from The Motley Fool, Business Upturn, and Zacks Investment Research, among other publications. This section is updated as new stories emerge, ensuring readers have access to the most current information shaping this part of the pharmaceutical landscape.

For authoritative reference, BSE Healthcare Index and NSE Pharma Sector publish official guidance and regulatory documentation relevant to these topics. Peer-reviewed research and clinical data can be accessed through IQVIA Industry Reports.

Showing 30 articles